157 related articles for article (PubMed ID: 38905267)
21. Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.
Rocha CM; Alves AM; Bettanin BF; Majolo F; Gehringer M; Laufer S; Goettert MI
Inflammopharmacology; 2021 Jun; 29(3):595-615. PubMed ID: 34046798
[TBL] [Abstract][Full Text] [Related]
22. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC; Song GG
Rheumatol Int; 2015 Dec; 35(12):1965-74. PubMed ID: 25994093
[TBL] [Abstract][Full Text] [Related]
24. JAK inhibitors in chronic plaque psoriasis: What is known so far.
Plachouri KM; Georgiou S
Drugs Today (Barc); 2020 Feb; 56(2):151-163. PubMed ID: 32163530
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials.
Cai W; Tong R; Sun Y; Yao Y; Zhang J
Front Pharmacol; 2024; 15():1387585. PubMed ID: 38725657
[TBL] [Abstract][Full Text] [Related]
26. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
Bechman K; Subesinghe S; Norton S; Atzeni F; Galli M; Cope AP; Winthrop KL; Galloway JB
Rheumatology (Oxford); 2019 Oct; 58(10):1755-1766. PubMed ID: 30982883
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2020 Jun; 58(6):293-298. PubMed ID: 32301699
[TBL] [Abstract][Full Text] [Related]
28. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
[TBL] [Abstract][Full Text] [Related]
29. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Jun; 82(5):408-416. PubMed ID: 34716775
[TBL] [Abstract][Full Text] [Related]
30. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Iwata S; Tanaka Y
Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
[TBL] [Abstract][Full Text] [Related]
31. Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Lee YH; Song GG
Clin Drug Investig; 2020 Jan; 40(1):65-72. PubMed ID: 31602572
[TBL] [Abstract][Full Text] [Related]
32. Risk of Venous Thromboembolism Associated With Tofacitinib and Baricitinib: A Systematic Review and Indirect Meta-Analysis.
Giménez Poderós T; Gallardo Borge S; Vazquez-Ferreiro P
Pharmacotherapy; 2020 Dec; 40(12):1248-1264. PubMed ID: 33064892
[TBL] [Abstract][Full Text] [Related]
33. The Risk of Infections Associated With JAK Inhibitors in Rheumatoid Arthritis: A Systematic Review and Network Meta-analysis.
Alves C; Penedones A; Mendes D; Marques FB
J Clin Rheumatol; 2022 Mar; 28(2):e407-e414. PubMed ID: 33902098
[TBL] [Abstract][Full Text] [Related]
34. Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.
Opdam MAA; Broeder ND; van den Bemt BJF; Mulder K; van de Wiel KM; van Ballegooijen H; van Crevel R; den Broeder AA
Clin Rheumatol; 2024 Jun; 43(6):2133-2138. PubMed ID: 38703283
[TBL] [Abstract][Full Text] [Related]
35. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
Chen M; Dai SM
Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
[TBL] [Abstract][Full Text] [Related]
36. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Nash P; Kerschbaumer A; Dörner T; Dougados M; Fleischmann RM; Geissler K; McInnes I; Pope JE; van der Heijde D; Stoffer-Marx M; Takeuchi T; Trauner M; Winthrop KL; de Wit M; Aletaha D; Baraliakos X; Boehncke WH; Emery P; Isaacs JD; Kremer J; Lee EB; Maksymowych WP; Voshaar M; Tam LS; Tanaka Y; van den Bosch F; Westhovens R; Xavier R; Smolen JS
Ann Rheum Dis; 2021 Jan; 80(1):71-87. PubMed ID: 33158881
[TBL] [Abstract][Full Text] [Related]
37. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
38. Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis.
Li Y; Yao C; Xiong Q; Xie F; Luo L; Li T; Feng P
J Clin Pharm Ther; 2022 Jul; 47(7):851-859. PubMed ID: 35253941
[TBL] [Abstract][Full Text] [Related]
39. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
Qiu Q; Feng Q; Tan X; Guo M
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):547-554. PubMed ID: 31059310
[No Abstract] [Full Text] [Related]
40. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
